Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: a systematic review
D Atwine, M Bonnet, AM Taburet - British Journal of Clinical …, 2018 - Wiley Online Library
Aims Efavirenz (EFV) and rifampicin–isoniazid (RH) are cornerstone drugs in human
immunodeficiency virus (HIV)–tuberculosis (TB) coinfection treatment but with complex drug …
immunodeficiency virus (HIV)–tuberculosis (TB) coinfection treatment but with complex drug …
[HTML][HTML] African Pharmacogenomics Consortium: consolidating pharmacogenomics knowledge, capacity development and translation in Africa: consolidating …
C Dandara, C Masimirembwa, YZ Haffani… - AAS Open …, 2019 - ncbi.nlm.nih.gov
Abstract The African Pharmacogenomics Consortium (APC) was formally launched on the
6th September 2018. This white paper outlines its vision, and objectives towards addressing …
6th September 2018. This white paper outlines its vision, and objectives towards addressing …
The pharmacological challenges of treating tuberculosis and HIV coinfections
EF Egelund, L Dupree, E Huesgen… - Expert Review of …, 2017 - Taylor & Francis
Introduction: Tuberculosis (TB) is the most prevalent opportunistic infection among HIV
patients, and the leading cause of death among HIV patients worldwide. Simultaneous …
patients, and the leading cause of death among HIV patients worldwide. Simultaneous …
[PDF][PDF] British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019
M Bracchi, C van Halsema, F Post, F Awosusi… - HIV …, 2019 - research.ed.ac.uk
These guidelines update the previously published BHIVA guidelines on the treatment of
TB/HIV co-infection from 2011 [1] and are designed to provide a clinical framework …
TB/HIV co-infection from 2011 [1] and are designed to provide a clinical framework …
Impact of population and pharmacogenetics variations on efavirenz pharmacokinetics and immunologic outcomes during anti-tuberculosis co-therapy: a parallel …
S Mugusi, A Habtewold, E Ngaimisi… - Frontiers in …, 2020 - frontiersin.org
Efavirenz-based combination antiretroviral-therapy (cART) is the recommended regimen
during tuberculosis (TB) therapy. In a multi-national parallel prospective-cohort study, we …
during tuberculosis (TB) therapy. In a multi-national parallel prospective-cohort study, we …
Early or deferred initiation of efavirenz during rifampicin‐based TB therapy has no significant effect on CYP3A induction in TB‐HIV infected patients
Background and Purpose In TB‐HIV co‐infection, prompt initiation of TB therapy is
recommended but anti‐retroviral treatment (ART) is often delayed due to potential drug …
recommended but anti‐retroviral treatment (ART) is often delayed due to potential drug …
Prevalence and risk factors for efavirenz-based antiretroviral treatment–associated severe vitamin D deficiency: A prospective cohort study
H Nylén, A Habtewold, E Makonnen, G Yimer… - Medicine, 2016 - journals.lww.com
Initiation of efavirenz-based combination antiretroviral therapy (cART) is associated with
Vitamin D deficiency, but the risk factors including efavirenz pharmacokinetics for cART …
Vitamin D deficiency, but the risk factors including efavirenz pharmacokinetics for cART …
CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women
CR Röhrich, BI Drögemöller, O Ikediobi… - AIDS research and …, 2016 - liebertpub.com
Long-term exposure to efavirenz (EFV) measured in hair samples may predict response to
antiretroviral treatment (ART). Polymorphisms in CYP2B6 are known to alter EFV levels. The …
antiretroviral treatment (ART). Polymorphisms in CYP2B6 are known to alter EFV levels. The …
Population pharmacokinetic model linking plasma and peripheral blood mononuclear cell concentrations of efavirenz and its metabolite, 8-hydroxy-efavirenz, in hiv …
A Habtewold, E Aklillu, E Makonnen… - Antimicrobial agents …, 2017 - Am Soc Microbiol
The objectives of this study were to characterize the population pharmacokinetics (PK) of
efavirenz (EFV) and 8-hydroxy-efavirenz (8OHEFV) in plasma and peripheral blood …
efavirenz (EFV) and 8-hydroxy-efavirenz (8OHEFV) in plasma and peripheral blood …
CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population
JK Mukonzo, RK Bisaso, J Ogwal-Okeng… - …, 2016 - Taylor & Francis
Aim: To assess genotype effect on efavirenz (EFV) pharmacokinetics, treatment outcomes
and provide genotype-based EFV doses recommendations during for tuberculosis (TB)-HIV …
and provide genotype-based EFV doses recommendations during for tuberculosis (TB)-HIV …